Small vaccine trial for coronavirus gets encouraging results
An experimental vaccine against the coronavirus showed encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers, its maker announced Monday.
Study volunteers given either a low or medium dose of the vaccine by Cambridge, Massachusetts-based Moderna Inc. had antibodies similar to those seen in people who have recovered from COVID-19.
In the next phase of the study, led by the U.S. National Institutes of Health, researchers will try to determine which dose is best for a definitive experiment that they aim to start in July.
In all, 45 people have received one or two shots of the vaccine, which was being tested at three different doses. The kind of detailed antibody results needed to assess responses are only available on eight volunteers so far.
The vaccine seems safe, the company said, but much more extensive testing is needed to see if it remains so. A high dose version is being dropped after spurring some short-term side effects.
The results have not been published and are only from the first of three stages of testing that vaccines and drugs normally undergo. U.S. government officials have launched a project called “Operation Warp Speed” to develop a vaccine and hopefully have 300 million doses by January.
Worldwide, about a dozen vaccine candidates are in the first stages of testing or nearing it. Health officials have said that if all goes well, studies of a potential vaccine might wrap up by very late this year or early next year.
More than 4.7 million infections and 315,000 deaths from the coronavirus have been confirmed worldwide since it emerged in China late last year. There are no specific approved treatments, although several are being used on an emergency basis after showing some promise in preliminary testing.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.